Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)

NCT05114096 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 3254

Last updated 2026-01-07

No results posted yet for this study

Summary

Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome.

The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity.

The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the standard double doses.

Conditions

  • Preterm Birth
  • Premature Birth
  • Complication of Prematurity
  • Obstetric Labor, Premature
  • Pregnancy Complications

Interventions

DRUG

Celestone + placebo

After the first intramuscular injection of Celestone, participants randomized to the "Placebo Comparator" group will receive 1 intramuscular injection of placebo.

DRUG

Celestone + Celestone

After the first intramuscular injection of Celestone, participants randomized to the "Active Comparator" group will receive 1 intramuscular injection of Celestone.

Sponsors & Collaborators

  • Hamilton Health Sciences Corporation

    collaborator OTHER
  • Sunnybrook Research Institute

    collaborator OTHER
  • Women's and Children's Hospital, Australia

    collaborator OTHER_GOV
  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV
  • Medical Research Future Fund

    collaborator OTHER
  • University of Adelaide

    collaborator OTHER
  • McMaster University

    lead OTHER

Principal Investigators

  • Sarah D McDonald, MD,MSc,FRCSC · McMaster University

  • Kellie Murphy, MD,MSc,FRCSC · University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-20
Primary Completion
2026-12-31
Completion
2029-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05114096 on ClinicalTrials.gov